Zanubrutinib bulk supplier for pharma manufacturers

Zanubrutinib 80mg, 160mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 80mg, 160mg

Reference Brands: Brukinsa (USA/EU)

Zanubrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling, thereby reducing the growth and survival of malignant B cells. It is approved for the treatment of mantle cell lymphoma, CLL/SLL, and Waldenström’s macroglobulinemia. Zanubrutinib offers high selectivity with fewer off-target effects compared to earlier BTK inhibitors.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Zanubrutinib — third party manufacturing & bulk supply

Zanubrutinib 80mg, 160mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Zanubrutinib is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Zanubrutinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Zanubrutinib →

Back to Listing

Frequently Asked Questions

Zanubrutinib is listed as Capsules in 80mg, 160mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Zanubrutinib is referenced against Brukinsa (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.